A Recombinant Newcastle Disease Virus (NDV) Expressing VP2 Protein of Infectious Bursal Disease Virus (IBDV) Protects Against NDV and IBDV

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2004 Aug 28

PMID 15331738

Citations 62

Authors

Zhuhui Huang

Subbiah Elankumaran

Abdul S Yunus

Siba K Samal

Affiliations

Soon will be listed here.

Abstract

Infectious bursal disease virus (IBDV) causes a highly immunosuppressive disease in chickens. Currently available, live IBDV vaccines can lead to generation of variant viruses. We have developed an alternative vaccine that will not create variant IBDV. By using the reverse genetics approach, we devised a recombinant Newcastle disease virus (NDV) vector from a commonly used vaccine strain LaSota to express the host-protective immunogen VP2 of a variant IBDV strain GLS-5. The gene encoding the VP2 protein of the IBDV was inserted into the most 3'-proximal locus of a full-length NDV cDNA for high-level expression. We successfully recovered the recombinant virus, rLaSota/VP2. The rLaSota/VP2 was genetically stable, at least up to 12 serial passages in chicken embryos, and was shown to express the VP2 protein. The VP2 protein was not incorporated into the virions of recombinant virus. Recombinant rLaSota/VP2 replicated to a titer similar to that of parental NDV strain LaSota in chicken embryos and cell cultures. To assess protective efficacy of the rLaSota/VP2, 2-day-old specific-pathogen-free chickens were vaccinated with the recombinant virus and challenged with a highly virulent NDV strain Texas GB or IBDV variant strain GLS-5 at 3 weeks postvaccination. Vaccination with rLaSota/VP2 generated antibody responses against both NDV and IBDV and provided 90% protection against NDV and IBDV. Booster immunization induced higher levels of antibody responses against both NDV and IBDV and conferred complete protection against both viruses. These results indicate that the recombinant NDV can be used as a vaccine vector for other avian pathogens.

Citing Articles

A novel approach for efficient co-expression of two foreign genes based on the reverse genetic system of Newcastle disease virus.

Lan T, Liu Q, Ge J, Wang Y Front Microbiol. 2025; 15:1442551.

PMID: 39744396 PMC: 11689658. DOI: 10.3389/fmicb.2024.1442551.

Evaluation of the immune responses of biological adjuvant bivalent vaccine with three different insertion modes for ND and IBD.

Sun W, Li S, Niu D, Qin R, Li H, Xue Z Virulence. 2024; 15(1):2387181.

PMID: 39101682 PMC: 11302549. DOI: 10.1080/21505594.2024.2387181.

Negative-Strand RNA Virus-Vectored Vaccines.

Murr M, Mettenleiter T Methods Mol Biol. 2024; 2786:51-87.

PMID: 38814390 DOI: 10.1007/978-1-0716-3770-8_3.

Simultaneous construction strategy using two types of fluorescent markers for HVT vector vaccine against infectious bursal disease and H9N2 avian influenza virus by NHEJ-CRISPR/Cas9.

Zhang J, Shang K, Kim S, Park J, Wei B, Jang H Front Vet Sci. 2024; 11:1385958.

PMID: 38812565 PMC: 11135205. DOI: 10.3389/fvets.2024.1385958.

Towards a Safer Future: Enhancing Vaccine Development to Combat Animal Coronaviruses.

Si F, Yu R, Dong S, Chen B, Li C, Song S Vaccines (Basel). 2024; 12(3).

PMID: 38543964 PMC: 10974119. DOI: 10.3390/vaccines12030330.

References

Tsukamoto K, Saito S, Saeki S, Sato T, Tanimura N, Isobe T . Complete, long-lasting protection against lethal infectious bursal disease virus challenge by a single vaccination with an avian herpesvirus vector expressing VP2 antigens. J Virol. 2002; 76(11):5637-45. PMC: 137028. DOI: 10.1128/jvi.76.11.5637-5645.2002. View

Vakharia V, Snyder D, Lutticken D, Savage P, Edwards G, Goodwin M . Active and passive protection against variant and classic infectious bursal disease virus strains induced by baculovirus-expressed structural proteins. Vaccine. 1994; 12(5):452-6. DOI: 10.1016/0264-410x(94)90124-4. View

Snyder D, Lana D, Savage P, Yancey F, Mengel S, Marquardt W . Differentiation of infectious bursal disease viruses directly from infected tissues with neutralizing monoclonal antibodies: evidence of a major antigenic shift in recent field isolates. Avian Dis. 1988; 32(3):535-9. View

Walsh E, Baron M, Anderson J, Barrett T . Development of a genetically marked recombinant rinderpest vaccine expressing green fluorescent protein. J Gen Virol. 2000; 81(Pt 3):709-18. DOI: 10.1099/0022-1317-81-3-709. View

Sakaguchi M, Nakamura H, Sonoda K, Okamura H, Yokogawa K, Matsuo K . Protection of chickens with or without maternal antibodies against both Marek's and Newcastle diseases by one-time vaccination with recombinant vaccine of Marek's disease virus type 1. Vaccine. 1998; 16(5):472-9. DOI: 10.1016/s0264-410x(97)80001-1. View

Palese P, Zheng H, Engelhardt O, Pleschka S, Garcia-Sastre A . Negative-strand RNA viruses: genetic engineering and applications. Proc Natl Acad Sci U S A. 1996; 93(21):11354-8. PMC: 38061. DOI: 10.1073/pnas.93.21.11354. View

de Leeuw O, Peeters B . Complete nucleotide sequence of Newcastle disease virus: evidence for the existence of a new genus within the subfamily Paramyxovirinae. J Gen Virol. 1999; 80 ( Pt 1):131-136. DOI: 10.1099/0022-1317-80-1-131. View

Peeters B, Gruijthuijsen Y, de Leeuw O, Gielkens A . Genome replication of Newcastle disease virus: involvement of the rule-of-six. Arch Virol. 2000; 145(9):1829-45. DOI: 10.1007/s007050070059. View

Heine H, Haritou M, Failla P, Fahey K, Azad A . Sequence analysis and expression of the host-protective immunogen VP2 of a variant strain of infectious bursal disease virus which can circumvent vaccination with standard type I strains. J Gen Virol. 1991; 72 ( Pt 8):1835-43. DOI: 10.1099/0022-1317-72-8-1835. View

10.

Park K, Huang T, Correia F, Krystal M . Rescue of a foreign gene by Sendai virus. Proc Natl Acad Sci U S A. 1991; 88(13):5537-41. PMC: 51912. DOI: 10.1073/pnas.88.13.5537. View

11.

Yokoyama N, Maeda K, Mikami T . Recombinant viral vector vaccines for the veterinary use. J Vet Med Sci. 1997; 59(5):311-22. DOI: 10.1292/jvms.59.311. View

12.

Becht H, Muller H, Muller H . Comparative studies on structural and antigenic properties of two serotypes of infectious bursal disease virus. J Gen Virol. 1988; 69 ( Pt 3):631-40. DOI: 10.1099/0022-1317-69-3-631. View

13.

Haglund K, Forman J, Krausslich H, Rose J . Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope. Virology. 2000; 268(1):112-21. DOI: 10.1006/viro.1999.0120. View

14.

Peeters B, de Leeuw O, Koch G, Gielkens A . Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol. 1999; 73(6):5001-9. PMC: 112544. DOI: 10.1128/JVI.73.6.5001-5009.1999. View

15.

Roberts A, Kretzschmar E, Perkins A, Forman J, Price R, Buonocore L . Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol. 1998; 72(6):4704-11. PMC: 109996. DOI: 10.1128/JVI.72.6.4704-4711.1998. View

16.

Huang Z, Krishnamurthy S, Panda A, Samal S . High-level expression of a foreign gene from the most 3'-proximal locus of a recombinant Newcastle disease virus. J Gen Virol. 2001; 82(Pt 7):1729-1736. DOI: 10.1099/0022-1317-82-7-1729. View

17.

Nakaya T, Cros J, Park M, Nakaya Y, Zheng H, Sagrera A . Recombinant Newcastle disease virus as a vaccine vector. J Virol. 2001; 75(23):11868-73. PMC: 114773. DOI: 10.1128/JVI.75.23.11868-11873.2001. View

18.

Mayo M . A summary of taxonomic changes recently approved by ICTV. Arch Virol. 2002; 147(8):1655-63. DOI: 10.1007/s007050200039. View

19.

Snyder D, Vakharia V, Savage P . Naturally occurring-neutralizing monoclonal antibody escape variants define the epidemiology of infectious bursal disease viruses in the United States. Arch Virol. 1992; 127(1-4):89-101. DOI: 10.1007/BF01309577. View

20.

Phenix K, Wark K, Luke C, Skinner M, Smyth J, Mawhinney K . Recombinant Semliki Forest virus vector exhibits potential for avian virus vaccine development. Vaccine. 2001; 19(23-24):3116-23. DOI: 10.1016/s0264-410x(01)00026-3. View